Vilin Bio Med reported a 763% surge in net profit to ₹192.88 lakh for the financial year ended March 31, 2026, driven by a significant increase in revenue from operations. The company's revenue from operations jumped 185% to ₹4,226.30 lakh from ₹1,480.99 lakh in the previous year. Earnings per share (EPS) for the year improved to ₹1.37 from ₹0.16 in FY25.

The Board of Directors approved the audited financial results for the year and half-year ended March 31, 2026, in a meeting held on May 30, 2026. The results were reviewed by the Audit Committee and audited by the Statutory Auditors, PPKG & Co, Chartered Accountants. The auditors issued an unmodified opinion on the standalone financial results.

Total expenses for FY26 increased to ₹3,942.33 lakh from ₹1,497.26 lakh in the prior year, primarily due to higher costs of materials consumed, which rose to ₹3,762.74 lakh. Finance costs decreased significantly to ₹6.88 lakh from ₹84.51 lakh. The company's profit before tax for the year stood at ₹284.09 lakh, compared to ₹30.58 lakh in the previous year.

Financial Performance for FY26

Capital Allocation and Fund Utilisation

During the financial year, the company allotted 13,00,000 equity shares on a preferential basis at a face value of ₹10 and a premium of ₹16 per share, raising ₹338.00 lakh. The company confirmed that there was no deviation or variation in the utilisation of funds raised through the preferential issue. Of the total amount raised, ₹197.93 lakh has been utilised, with a balance of ₹140.07 lakh maintained with a scheduled commercial bank.

The trading window for dealing in the company's securities, which was closed from April 1, 2026, will open 48 hours after the declaration of the audited standalone financial results.

Vilin Bio Med has confirmed that its promoters and persons acting in concert (PACs) did not create any encumbrance on their shareholding during the financial year ended March 31, 2026. This disclosure was submitted to the National Stock Exchange on April 6, 2026, in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The confirmation assures investors that the pledged status of promoter shares remained unchanged throughout the fiscal year.

The filing detailed the shareholding of 15 individuals categorized as promoters, members of the promoter group, and PACs. The data provides transparency regarding the ownership structure and the specific number of shares held by each member of the promoter group. The total shares held by promoters and the promoter group collectively amount to 90,04,374 shares, while PACs hold 24,000 shares.

Promoter and PAC Shareholding Details

The following table outlines the shareholding distribution among the members of the promoter group and PACs as of the financial year ended March 31, 2026:

The disclosure was signed by Madhusudhan Yadamakanti Reddy, Managing Director of Vilin Bio Med, and submitted to the exchange for record purposes. The company operates from its registered office in Hyderabad and maintains a manufacturing unit in Roorkee, Haridwar.